32 completed, 7 terminated, 4 active not recruiting, 4 not yet recruiting. 52 Phase 2, 8 Phase 1, 1 Phase 3.
Follow Cranial Nerve Neoplasms: new trials by email Literature Review of Cranial Nerve Neoplasms trials Research Report on Cranial Nerve Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-12-01 | 2026-10-28 |
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-07-18 | 2026-07-20 |
| Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II Trineumin - Neurofibromatosis Type II, NF2 | Phase 1 / Phase 2 | Not yet recruiting | PRG Science & Technology Co., Ltd. | 25 | 2026-07-01 | 2026-01-23 |
| Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 27 | 2025-01-17 | 2026-11-04 |
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Completed | Reveal Pharmaceuticals Inc. | 18 | 2024-08-15 | 2025-12-26 |
| Doxycycline in Cutaneous Schwannoma (NF2) Doxycycline Injection [Doxy] - Neurofibromatosis Type 2 | Phase 1 / Phase 2 | Active not recruiting | Massachusetts Eye and Ear Infirmary | 19 | 2022-09-19 | 2026-10-16 |
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas REC-2282, Placebo - Neurofibromatosis Type 2 | Phase 2 / Phase 3 | Terminated | Recursion Pharmaceuticals Inc. | 25 | 2022-06-20 | 2026-08-17 |
| Modified CV Regimen in Optic Pathway Glioma Carboplatin, Vincristine, Recombinant human endostatin - Optic Glioma, Pediatric Brain Tumor, Optic Nerve Glioma | Phase 2 | Recruiting | Beijing Sanbo Brain Hospital | 75 | 2022-04-13 | 2024-10-15 |
| Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Fluorescein Sodium, YELLOW560 filter - Vestibular Schwannoma | Phase 2 | Completed | Mayo Clinic | 12 | 2021-10-06 | 2023-08-01 |
| Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System tozuleristide, Canvas imaging system, Surgical resection of tumor - Central Nervous System Tumor | Phase 2 | Completed | John Yu | 50 | 2021-09-30 | 2026-07-10 |
| Nimodipine in Vestibular Schwanommas NiMODipine Injectable Solution, Placebo - Vestibular Schwannoma | Phase 2 | Unknown | Medical University of Vienna | 30 | 2021-05-04 | 2023-10-19 |
| Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Brigatinib, Neratinib, Retifanlimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Recruiting | Scott R. Plotkin, MD, PhD | 109 | 2020-06-20 | 2026-11-12 |
| Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Crizotinib - Neurofibromatosis 2, Progressive Vestibular Schwannoma (VS) | Phase 2 | Completed | University of Alabama at Birmingham | 12 | 2020-02-18 | 2026-03-13 |
| Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Selumetinib - Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 1 / Phase 2 | Completed | Great Ormond Street Hospital for Children NHS Foundation Trust | 14 | 2019-09-26 | 2024-04-04 |
| Study of Aspirin in Patients With Vestibular Schwannoma Aspirin, Placebo - Vestibular Schwannoma, Acoustic Neuroma | Phase 2 | Active not recruiting | Massachusetts Eye and Ear Infirmary | 97 | 2018-03-01 | 2026-10-16 |
| RGD PET/MRI in Sporadic Vestibular Schwannoma One injection of 68Ga-NODAGA-E[c(RGDyK)]2 - Acoustic Neuroma | Phase 2 | Unknown | Copenhagen University Hospital, Rigshospitalet | 40 | 2018-01-02 | 2018-01-10 |
| Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma Laboratory Biomarker Analysis, Selumetinib Sulfate - Cutaneous Neurofibroma, Neurofibromatosis Type 1 | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2017-08-26 | 2023-12-06 |
| Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Selumetinib - Neurofibromatosis 2, Vestibular Schwannoma | Phase 2 | Terminated | Children's Hospital Medical Center, Cincinnati | 10 | 2017-05-08 | 2025-04-22 |
| AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas AZD2014 - Neurofibromatosis 2, Meningioma | Phase 2 | Completed | Massachusetts General Hospital | 18 | 2016-08-31 | 2022-06-13 |
Showing 20 of 52. Sign in to see all of them.
Neurofibromatosis 2 (24) · Neuroma, Acoustic (22) · Optic Nerve Glioma (21) · Astrocytoma (19) · Oligodendroglioma (14) · Central Nervous System Neoplasms (13) · Meningioma (12) · Brain Neoplasms (11) · Medulloblastoma (10) · Ependymoma (9) · Familial ependymoma (9) · Glioma (9) · Glioblastoma (6) · Neuroblastoma (6) · Choroid Plexus Neoplasms (5)
Cranial Nerve Diseases (52) · Neoplasms by Histologic Type (52) · Neoplasms, Nerve Tissue (52) · Nervous System Diseases (52) · Neuroectodermal Tumors (52) · Neoplasms (51) · Neoplasms, Germ Cell and Embryonal (50) · Neoplasms by Site (46) · Nervous System Neoplasms (46) · Peripheral Nervous System Neoplasms (43) · Nerve Sheath Neoplasms (34) · Neuroendocrine Tumors (33) · Otorhinolaryngologic Neoplasms (33) · Otorhinolaryngologic Diseases (32)
Bevacizumab (5) · Carboplatin (5) · AZD 6244 (4) · Everolimus (3) · Radiotherapy (3) · Temozolomide (3) · Doxorubicin (2) · Endostatins (2) · Irinotecan (2) · Vincristine (2) · etoposide phosphate (2) · Aspirin (1) · Axitinib (1) · Blotting, Western (1) · Cilengitide (1)
National Cancer Institute (NCI) (8) · Beijing Tiantan Hospital (4) · Duke University (3) · NYU Langone Health (3) · Children's Oncology Group (2) · Massachusetts Eye and Ear Infirmary (2) · Massachusetts General Hospital (2) · Memorial Sloan Kettering Cancer Center (2) · University of Alabama at Birmingham (2) · Assistance Publique - Hôpitaux de Paris (1) · Beijing Sanbo Brain Hospital (1) · Children's Hospital Medical Center, Cincinnati (1) · City of Hope Medical Center (1) · Copenhagen University Hospital, Rigshospitalet (1) · Eli Lilly and Company (1)
United States (39) · Canada (8) · China (6) · Australia (4) · New Zealand (4) · Puerto Rico (4) · Switzerland (3) · Netherlands (2) · United Kingdom (2) · Austria (1) · Denmark (1) · France (1)
Henry S. Friedman, MD (3) · Matthias A Karajannis, MD, MS (3) · D. Bradley Welling, MD, PhD (2) · Fu Zhao (2) · Pinan Liu (2) · Scott Plotkin, MD (2) · Aaron Tward, MD (1) · Andrew Cluster, M.D. (1) · Anne-Marie Langevin, MD (1) · Bruce R Korf (1) · Darren Hargrave, MB Bch (1) · Dorian Hirschmann, MD (1) · Edward G. Shaw, MD (1) · Girish Dhall, MD (1) · Harry T Whelan, MD (1)
PMID 16408203, PMID 17610262, PMID 18989154, PMID 20381270, PMID 26976425, PMID 35229827, PMID 36240730, PMID 37126770, PMID 38372904, PMID 38904277, PMID 38907342, PMID 40009403, PMID 41530428, PMID 42788739
U10CA098543 (5), 2017 (1), P30CA006973 (1), P30CA013148 (1), P30CA033572 (1), R44CA261240 (1), U10CA081920 (1), U10CA180886 (1)